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Background. Epstein-Barr virus (EBV) is associated with a number of human malignancies. EBV-positive post-transplant
lymphoproliferative disease in solid organ and hematopoietic stem cell transplant recipients has been successfully treated by
the adoptive transfer of polyclonal EBV-specific T cell lines containing CD4+ and CD8+ T cell components. Although patients
receiving T cell preparations with a higher CD4+ T cell proportion show better clinical responses, the specificity of the infused
CD4+ component has remained completely unknown. Methodology/Principal Findings. We generated LCL-stimulated T cell
lines from 21 donors according to clinical protocols, and analyzed the antigen specificity of the CD4+ component in EBV-
specific T cell preparations using a genetically engineered EBV mutant that is unable to enter the lytic cycle, and recombinantly
expressed and purified EBV proteins. Surprisingly, CD4+ T cell lines from acutely and persistently EBV-infected donors
consistently responded against EBV lytic cycle antigens and autoantigens, but barely against latent cycle antigens of EBV
hitherto considered principal immunotherapeutic targets. Lytic cycle antigens were predominantly derived from structural
proteins of the virus presented on MHC II via receptor-mediated uptake of released viral particles, but also included abundant
infected cell proteins whose presentation involved intercellular protein transfer. Importantly, presentation of virion antigens
was severely impaired by acyclovir treatment of stimulator cells, as currently performed in most clinical protocols.
Conclusions/Significance. These results indicate that structural antigens of EBV are the immunodominant targets of CD4+ T
cells in LCL-stimulated T cell preparations. These findings add to our understanding of the immune response against this
human tumor-virus and have important implications for the improvement of immunotherapeutic strategies against EBV.
Citation: Adhikary D, Behrends U, Boerschmann H, Pfu¨nder A, Burdach S, et al (2007) Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-
Specific CD4+ T Cell Preparations for Therapy. PLoS ONE 2(7): e583. doi:10.1371/journal.pone.0000583
INTRODUCTION
Epstein-Barr virus (EBV) is a ubiquitous human c-herpesvirus
implicated in the etiology of several tumors of lymphoid and
epithelial origin [1–3]. Primary infection with EBV usually occurs
early in life by parent-to-child oral transmission in an almost
always asymptomatic fashion. Delayed primary infection in
adolescence or adulthood may cause the syndrome of infectious
mononucleosis (IM), a self-limiting lymphoproliferative disease [4].
After oral transmission, the virus replicates in the oropharynx,
probably in the mucosal epithelium, from where it colonizes the
host by latently infecting B cells. The reservoir of latently infected
B cells can seed foci of virus replication at mucosal sites, and this
reactivation of the virus and subsequent re-infection of B
lymphocytes allows the virus to persist for life in the infected
human host [5]. In B cells, EBV is able to establish different types
of latency characterized by the expression of different sets of viral
genes. During the primary phase of B cell infection, as well as in
lymphoblastoid cell lines (LCL) generated by infection of B cells
with EBV in vitro, the full range of eight antigenically distinct
latent cycle proteins is expressed that drive the activation and
proliferation of the infected cell [6,7].
In vivo, outgrowth of latently infected growth-transformed B
cells is curtailed by T cells. The importance of T cell-mediated
immune responses in maintaining asymptomatic viral persistence
is emphasized by the clinical observation that patients with T cell
dysfunction are at risk of developing life-threatening EBV-
associated lymphoproliferative disease [3]. In solid organ and
hematopoietic stem cell transplant (HSCT) recipients, incidence of
EBV-positive post-transplant lymphoproliferative disease (PTLD)
correlates with the degree of the iatrogenically induced immuno-
suppression [3,8]. Importantly, EBV-positive PTLD in HSCT
recipients has been successfully treated by the adoptive transfer of
EBV-specific T cell lines containing CD4+ and CD8+ compo-
nents. These polyclonal lines are generated by repeated stimula-
tion of peripheral blood T cells with irradiated autologous LCL in
vitro [9–11]. The targets of LCL-stimulated CD8+ T cells have
been studied in detail and display a marked hierarchy in
immunodominance with epitopes derived from the EBNA3 family
of proteins and immediate early as well as early lytic cycle proteins
usually inducing the strongest responses across a range of HLA
class I alleles [12–17]. The EBV-specific CD4+ T cell response is
less well defined. In a recent phase II clinical trial, patients with
PTLD showed better responses when the infused T cell prepar-
ations contained higher numbers of CD4+ T cells [18]. This study
inferred an important role of CD4+ T cells in controlling EBV-
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driven lymphoproliferation, but the specificity of the CD4+
component in LCL-stimulated T cell preparations has remained
completely unknown.
The proven safety and efficacy of adoptive T cell therapy for
PTLD in HSCT recipients has provided an important proof of
principle for this form of immunotherapy, but owing to the
considerable technical requirements and financial implications of
extensive in vitro T cell culture, adoptive T cell therapy still has
a limited role in the management of virus-associated complications
in transplant patients [19]. Nevertheless, despite a better un-
derstanding of PTLD pathogenesis and the development of early
detection strategies such as serial measurement of EBV DNA load
in peripheral blood samples, as well as the introduction of novel
therapeutic agents such as antiviral drugs or monoclonal
antibodies to CD20, adoptive T cell therapy is likely to remain
an important therapeutic option for patients with tumors that fail
to respond to antibody treatment, and to develop as a prophylactic
option for patients who are identified as being at immediate risk of
EBV-driven disease [8,20].
Moreover, the successful treatment of PTLD in immunocom-
promised transplant recipients has encouraged the extension of
these protocols to treat EBV-associated tumors developing in the
presence of an apparently competent immune system, e.g.
nasopharyngeal carcinoma (NPC) and Hodgkin’s disease (HD).
First clinical experience indicates that LCL-stimulated T cell lines
may cause tumor regression in some cases but clinical responses
are often partial and transient [21], most likely because of immune
evasion strategies by tumor cells such as non-expression of the
EBNA3 family of proteins, the immunodominant targets of the
latent antigen-specific CD8+ T cell response [3,8].
To increase clinical efficacy of the T cell preparations and to
implement this treatment modality as a conventional therapeutic
option, generic and more direct approaches for the generation of
EBV-specific T cell lines enriched in disease-relevant specificities
need to be developed. Prerequisite for the realization of these
objectives is the knowledge of the relevant T cell antigens. Here,
we studied the specificity of the CD4+ T cell component in LCL-
stimulated T cell preparations.
MATERIALS AND METHODS
Donors
Studies on material of human origin were approved by the ethics
committees of the universities involved, and informed consent was
obtained from all donors or their guardians. Blood samples from
serologically confirmed cases of acute IM were obtained from the
Children’s Hospital, Munich University of Technology. Cord
blood samples were provided by the University Hospital of the
Ludwig Maximilians University, Munich. Mononuclear cells were
isolated from blood samples by density gradient centrifugation on
Ficoll-Paque (GE Healthcare). All donors were HLA-typed using
PCR-based methods.
Cell culture
LCL and mini-LCL were established by infection of primary B
cells with B95.8 virus and the genetically engineered mini-EBV
strain, respectively [22]. LCL, mini-LCL, the B95.8 marmoset cell
line, and Burkitt’s lymphoma cell lines were grown as suspension
cultures in LCL media consisting of RPMI 1640, 10% fetal calf
serum (FCS), 1% nonessential amino acids, 1mM sodium
pyruvate, 2 mM L-glutamine, and 50 mg/ml gentamicin.
HEK293T cells were cultured in DMEM medium supplemented
with 10% FCS, 2 mM L-glutamine, and 50 mg/ml gentamicin. T
cells were cultured in AIM-V media (Invitrogen) supplemented
with 10% heat inactivated human serum, 2 mM L-glutamine, and
10mM HEPES. To avoid expansion of FCS-reactive T cells, all
APCs used for T cell stimulation were grown in LCL media
supplemented with 10% human serum instead of FCS. In some
experiments, LCL treated with 200 mM acyclovir (Hexal) for at
least for two weeks were used as T cell targets.
T cell lines were established by LCL or mini-LCL stimulation as
in clinical protocols [9,23]. After 4–8 passages, CD4+ cells were
isolated from the T cell lines by positive or negative selection using
a-CD4+ or a-CD8+ MicroBeads, LS-columns, and MidiMACS
separator as recommended by the manufacturer (Miltenyi Biotec).
T cell clones were generated by limiting dilution cloning in 96-well
round-bottom plates.
Dendritic cells were differentiated from precursors in peripheral
blood as described [24]. PHA blasts were generated by stimulating
106/ml PBMC with 250 ng/ml PHA in T cell media supplemen-
ted with 50IU IL-2/ml.
Phenotypic and functional analysis of T cells
For FACS analysis of T cells, FITC or PE-conjugated monoclonal
antibodies against human CD4, CD8, and TCRa/b were used (all
from Becton-Dickinson). TCR-Vb usage by T cells was analyzed
by RT-PCR and Southern blot. cDNA was synthesized from total
RNA extracted from T cells and PCR performed using primers
specific for the variable regions of the different human TCR-Vb
chains [25]. PCR products were separated in an agarose gel,
blotted onto Hybond-N+ membrane (GE Healthcare) and
hybridized with a TCR-Vb chain constant region probe. IFN-c
ELISPOT assays and cytokine ELISAs were performed essentially
as described [26]. Cytolytic activity of T cells was measured in
europium ligand release assays [22].
Preparation of concentrated EBV suspension
Cell free supernatant from B95.8 cells was filtered through
a 0.8 mm filter and ultracentrifuged at 25,0006 g for 3 hours in
a SW28 rotor (Beckman Coulter). The supernatant was removed
and the virus rich pellet resuspended in 1/20 volume of the
original culture supernatant. The number of EBV genome
equivalents (geq)/ml of this virus concentrate was determined by
semi-quantitative real-time PCR using primers directed to the
BALF5 gene [27].
Expression and purification of EBV proteins
The following EBV proteins were selected: the latent proteins
EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA-LP,
LMP1, LMP2A; the immediate early lytic cycle proteins BZLF1
and BRLF1, the early lytic cycle proteins BALF1, BALF2, BALF3,
BALF5, BaRF1, BARF1, BBLF2/BBLF3, BBLF4, BDLF4,
BFLF2, BFRF1, BGLF3, BGLF5, BHRF1, BKRF3, BKRF4,
BLLF3, BMLF1, BMRF1, BORF2, BRRF1, BVRF2, BXLF1,
and the late lytic cycle proteins BALF4, BBRF1, BBRF2, BBRF3,
BcLF1, BcRF1, BCRF1, BDLF1, BDLF3, BFRF3, BGLF1,
BGLF2, BILF2, BKRF2, BLLF1, BLRF1, BLRF2, BNRF1,
BOLF1, BORF1, BSLF1, BSRF1, BXLF2, BXRF1, BZLF2.
The cDNAs coding for latent cycle proteins were kindly provided
by Dr. W. Hammerschmidt (GSF, Munich), or cloned from
latently infected cells. The lytic cycle genes were amplified by PCR
from B95.8 virus DNA and all genes cloned into the CMV
promoter/enhancer driven mammalian expression vector pCMV-
EHis, tagging the EBV genes at their 39 end with sequences coding
for the epitope recognized by the monoclonal a-EBNA1 antibody
1H4, and a His-tag consisting of six consecutive histidines.
CD4+ T Cell Response to EBV
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For recombinant protein expression, the plasmids were
transiently transfected into HEK293T cells using the calcium
phosphate transfection method [28]. The cells were harvested 48
to 60 hours after transfection and lysed in urea lysis buffer (8 M
Urea, 0.1 M NaH2PO4, 0.01 M Tris, 0.05% Tween 20, 20 mM
imidazole; pH 8.0). Following centrifugation (5,0006g/15 min) to
pellet insoluble debris, the His-tagged proteins were purified using
Nickel-NTA agarose beads according to the guidelines of the
manufacturer (Qiagen). The protein eluate was dialysed against
PBS, the concentration determined using Bradford reagent
(BioRad), and the solutions brought to a concentration of
50 mg/ml. The proteins were separated by SDS-PAGE, and
identity and purity analyzed by Coomassie staining and by
Western blot using the 1H4 monoclonal antibody (kindly provided
by Dr. E. Kremmer, GSF, Munich) and the ECL plus detection
system (GE Healthcare). For antigen identification, APC were
incubated overnight with 1 mg/ml recombinant protein, excess
protein removed by washing, and probed with T cells.
RESULTS
Generation of CD4+ T cell lines using LCL as
stimulators
Using autologous LCL as stimulators, T cell lines were established
from mononuclear cells of umbilical or peripheral blood of 21
individuals; five cord blood donors, eight patients with IM, and eight
healthy adult volunteers of whom seven were EBV-seropositive and
one EBV-seronegative. As described for LCL-stimulated T cell lines
prepared for clinical applications [10,29], all T cell lines established
from EBV-seropositive donors lysed autologous LCL but not PHA
blasts after 4–8 rounds of stimulation (Fig. 1A). To study the CD4+T
cell components, all T cell lines were enriched for CD4+ T helper
(TH) cells by selecting CD4+ cells. FACS analysis of the sorted T cell
lines verified that all lines contained more than 95% TCRa/b+ and
CD4+ cells, and this phenotype was maintained over extended
periods of in vitro culture (Fig. 1B). When tested for target-specific
cytokine secretion, T cell lines from all EBV-positive donors
recognized autologous and allogeneic LCLs in an MHCII-restricted
fashion. LCL-stimulated TH cell lines from healthy virus carriers also
recognized MHCII-matched EBV-positive but not or only weakly
EBV-negative target cells (Fig. 1C left), indicating that these lines
were specific for EBV antigens. Of the eight T cell lines derived from
IM patients, three displayed EBV-specificity by these criteria
whereas five T cell lines responded similarly against EBV-negative
and EBV-positive target cells (Fig. 1C right), implying that these T
cells recognized self-antigen(s), or were specific for viral antigens and
coincidentally cross-reacted against alloantigens.
The five T cell lines derived from cord blood, and the T cell line
from the EBV-seronegative healthy adult barely recognized
autologous LCL (Fig. 1D). Because some of these cell lines
responded vigorously against MHCII-mismatched target cells, T
cell unresponsiveness was unlikely to account for this low
reactivity. These results demonstrated that EBV-specific TH cell
memory is efficiently reactivated by LCL stimulation, and
excluded that de novo priming of EBV-specific TH cell responses
occurs under these in vitro conditions.
Upon target cell recognition all LCL-reactive T cell lines
predominantly secreted Th1 cytokines (Fig. 1E), except for the T
cell line derived from IM7. This T cell line proliferated upon
stimulation with autologous LCL and IL-2 and was maintained in
culture for more than 50 passages, but failed to secrete any of the
cytokines tested in response to autologous or allogeneic targets or
when stimulated with PHA (Fig. 1F).
Latent cycle antigens of EBV are not the principal
targets of LCL-stimulated EBV-specific CD4+ T cells
The exclusive recognition of EBV-positive but not EBV-negative
targets by the T cell lines established from all healthy virus carriers
and three IM patients suggested that these T cells were directed
against latent cycle proteins of EBV. To define the TH cell
antigens molecularly, all eight antigenically distinct latent cycle
proteins of EBV were recombinantly expressed and the purified
proteins pulsed on autologous PBMC, which were subsequently
used as targets for the EBV-specific T cells. Efficient presentation
of peptides derived from latent cycle proteins on MHC II was
verified in control experiments using CD4+ T cell clones specific
for five of the latent antigens of EBV (data not shown).
Surprisingly, except for two T cell lines showing weak responses
against EBNA3C, none of the EBV-specific T cell lines recognized
any of the latent cycle antigens of EBV (Fig. 2). Because CD4+ T
cells specific for latent antigens of EBV have been isolated from
peripheral blood of healthy virus carriers by different groups
[26,30–33], and T cells specific for five different latent cycle
antigens have been isolated previously from three of the healthy
EBV-seropositive donors included in this study (data not shown),
the absence of latent cycle antigen-specific TH cell responses was
unlikely to account for these negative results. Since the precursor
frequency of such T cells in peripheral blood is generally low [33],
up to 50 restimulations were performed to facilitate the expansion
of such rare T cell specificities to detectable levels. No reactivity
against any of the latent cycle antigens was detected in these late
passage T cell lines. Even the weak responses against EBNA3C
were no longer detected (data not shown), indicating that LCL-
stimulated TH cell lines either target non-latent cycle antigens of
EBV or cellular antigens induced by EBV.
Lytic cycle antigens are the immunodominant
targets of EBV-specific CD4+ T cell lines
To address whether LCL-stimulated T cells recognize lytic cycle
antigens of EBV, mini-LCL incapable of expressing lytic cycle
proteins were established by infecting B cells with a genetically
engineered mutant strain of EBV and used as T cell targets
[22,34]. While early passage T cell lines responded similarly
against LCL and mini-LCL, responses against mini-LCL de-
creased to background levels with further rounds of stimulation in
all T cell lines that had shown EBV specificity in previous
experiments, suggesting that the late passage T cell lines
recognized lytic cycle antigens or cellular genes induced by EBV
infection (Fig. 3A). To assess the T cell responses against mini-LCL
versus LCL in more detail, IFN-c ELISPOT assays were
performed. Loss of mini-LCL reactivity became apparent after
three to twenty passages depending on the cell line analyzed, but
eventually all lines established from healthy virus carriers reacted
against LCL but not or minimally against mini-LCL (Fig. 3B). By
contrast, the four T cell lines established from patients with IM
that had shown EBV-independent LCL-reactivity in previous
experiments continued to respond against both types of target cells
(Fig. 3B). The recognition of EBV-negative target cells in earlier
experiments suggested that these lines targeted cellular antigens.
Immunodominance of autoantigens over viral latent
cycle antigens
The weak and transient responses against EBNA3C detected in
two of the T cell lines established from healthy virus carriers
implied that T cells specific for latent cycle antigens expanded
under these in vitro culture condition, albeit less efficiently than
CD4+ T Cell Response to EBV
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lytic cycle antigen-specific TH cells. To assess whether latent cycle
antigen-specific T cells are a subdominant component of the LCL-
stimulated TH cell response, CD4+ PBMC from the donors DA
and JM were repeatedly stimulated with autologous mini-LCL.
These donors were chosen because TH cell lines and clones
specific for EBV latent cycle antigens had been established
previously from their peripheral blood, predicating the presence of
such TH cell specificities in the peripheral memory compartment
(data not shown). The resulting T cell lines responded similarly
against autologous mini-LCL and LCL. Surprisingly, except for
weak responses against EBNA3C in donor DA, these lines failed to
recognize autologous PBMC or DC pulsed with any of the latent
cycle antigens of EBV even after more than 25 passages,
demonstrating that these T cell were not specific for latent
antigens of EBV, but targeted cellular antigen(s) (Fig. S1).
Immunodominance of virion antigens
To investigate if the LCL but not mini-LCL-reactive TH cell lines
recognized lytic cycle antigens, we cloned 50 of the more than 80
different lytic cycle genes of EBV including the immediate early
antigens BZLF1 and BRLF1, 23 early antigens, and 25 late
antigens. Mini-LCL were pulsed with the recombinantly expressed
and purified lytic cycle proteins and subsequently probed with the
Figure 1. Generation and characterization of LCL-stimulated CD4+ T cell lines. T cell lines established from EBV-positive donors by LCL stimulation
lysed autologous LCL but not PHA blasts after 4–8 passages at different effector-to-target (E:T) ratios. (B) FACS analysis of CD4+ cell lines established
from LCL-stimulated bulk T cell lines by magnetic sorting demonstrated that .95% of the cells were TCRa/b+ and CD4+. (C) As demonstrated for
donor GB, all TH cell lines established from healthy virus carriers responded against autologous and MHCII-matched allogeneic LCL, as well as MHCII-
matched EBV-positive (BL41-B95.8) but not EBV-negative (BL41) Burkitt’s lymphoma cell lines. TH cell lines from IM patients showed similar responses
against autologous LCL, but as exemplified by the T cell line from IM4, some of these lines also recognized EBV-negative BL cell lines. (D) LCL-
stimulated TH cell lines from EBV-negative donors showed minimal if any responses against autologous LCL, but vigorous responses against some
allogeneic targets. (E) EBV-reactive TH cell lines secreted GM-CSF, IFN-c, and TNF-a, but not IL-4, IL-10, IL-17, or TGF-b1 in response to stimulation with
autologous (GB) or MHCII-matched allogeneic (JM) LCL, or non-specific activation by PHA. The MHC-mismatched LCL DA served as negative control.
The following standards were included: GM-CSF: 1,900 pg/ml; IFN-c: pg/ml; IL-4: 250 pg/ml; IL-10: 2,100 pg/ml; TNF-a: 2,900 pg/ml; TGF-b1: 1,450 pg/
ml; IL-17: 1,700 pg/ml. (F) The T cell line IM7 displayed a novel ‘‘non-responder’’ phenotype. This T cell line proliferated in response to stimulation with
autologous LCL and IL-2, but failed to secrete any of the indicated cytokines even after stimulation with autologous LCL plus PHA.
doi:10.1371/journal.pone.0000583.g001
CD4+ T Cell Response to EBV
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Figure 2. Latent cycle antigens of EBV are not the principal targets of LCL-stimulated TH cells. EBV-specific TH cell lines from different donors at
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responded against EBV latent cycle proteins.
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Figure 3. EBV-reactive TH cell lines recognize autologous LCL but not mini-LCL. LCL-stimulated TH cell lines showing EBV reactivity were tested for
recognition of autologous LCL and mini-LCL established by infection of B cells with an EBV mutant unable to enter the lytic cycle. After three to
twenty passages, mini-LCL reactivity of all TH cell lines had dropped to background levels while responses against LCL were maintained even after
extended periods of in vitro culture. (B) Responses against LCL and mini-LCL of different passage TH cell lines were assessed by IFN-c ELISPOT. With
the exception of the T cell line from SM, early passage TH cell lines from healthy virus carriers recognized LCL and mini-LCL, but responses against
mini-LCL disappeared with further rounds of stimulation. By contrast, early and late passage T cell lines from IM3, which had failed to show EBV-
reactivity in earlier experiments, responded similarly against both types of target cells. SFC, spot forming cells.
doi:10.1371/journal.pone.0000583.g003
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T cell lines once mini-LCL reactivity had subsided. All T cell lines
recognized at least one of the lytic cycle antigens tested (Fig. 4).
Except for the lytic cycle proteins BMRF1, BCRF1, and BALF2,
all of the antigens identified were derived from virion proteins
(Table 1). Moreover, all lines targeted at least one virion antigen.
With the notable exception of the tegument protein BNRF1,
which was recognized by six of the ten T cell lines, diverse sets of
antigens were recognized by the different T cell lines, suggesting
that the immunodominant antigens of the LCL-stimulated TH cell
populations are derived from structural proteins of EBV (Table 1).
Late passage LCL-stimulated TH cell lines are still
oligoclonal
Although late passage T cell lines usually responded against a single
lytic cycle antigen, these experiments left unresolved whether these
lines were still oligoclonal and contained additional specificities
that remained undetected in these experiments e.g. lytic cycle
antigens that had not been included in this study. To address this
issue, two sets of experiments were performed. First, selected T cell
lines were cloned by limiting dilution and analyzed for antigen
specificity by assessing recognition of LCL, mini-LCL, and mini-
LCL pulsed with proteins identified as targets of the parental T cell
line. This analysis revealed that only a portion of the single cell
outgrowths was of expected specificity. For example, the clones
obtained from the T cell line MA passage p17 could be subdivided
into four groups: (i) those that recognized BNRF1 or BMRF1, the
previously identified targets of the parental T cell line, (ii) those
that recognized LCL but neither mini-LCL alone nor mini-LCL
pulsed with the recombinant BNRF1 or BMRF1, (iii) those that
responded against LCL as well as mini-LCL and (iv) those that
secreted neither GM-CSF nor IFN-c upon co-culture with the
target cells (Fig. S2). Thus, in addition to T cells recognizing the
antigens identified in the parental cell line, this line contained T
cells specific for additional and still unidentified lytic cycle
antigen(s), autoreactive T cells, and T cells with a similar non-
responder phenotype as noted before with the T cell line from
IM7. Since the antigens recognized by the last three types of T
cells were unknown, it remained unclear whether the clones within
the same group recognized one or several antigens. T cell clones
established from late passage T cell lines usually lacked autoanti-
gen-specificity, but still recognized more than one antigen (data
not shown). In a second set of experiments, TH cell lines were
analyzed for T cell receptor Vb chain (TCR-Vb) expression. TH
cell lines stimulated more than 40 times were still positive for more
than one TCR-Vb chain (Fig. S3), demonstrating that LCL-
stimulated TH cell lines from EBV-positive individuals remain
oligoclonal even beyond a year and a half in culture.
Presentation of lytic cycle antigens on MHC II
Given the low percentage of usually less than 1% of cells in an
LCL culture that spontaneously become permissive for lytic
replication, it was surprising to find that lytic cycle proteins of EBV
are the immunodominant targets recognized by LCL-stimulated T
cell lines. To investigate if structural proteins of EBV are presented
via the receptor-mediated presentation pathway recently described
for EBV glycoproteins [22], mini-LCL were pulsed with viral
particles and tested for recognition by virion-specific T cells.
Because purified EBV particles also contain low amounts of the
non-structural early lytic cycle proteins BALF2 and BMRF1 [35],
T cells specific for BMRF1 were included in this analysis. Mini-
LCL pulsed with less than 1 genome equivalent (geq)/cell were
recognized by all virion-specific, but not by BMRF1-specific T
cells, demonstrating that virion antigens are efficiently presented
on MHC II and that the number of BMRF1 molecules in virions is
probably insufficient for T cell detection (Fig. 5A). To address
whether the presentation of BMRF1 involved intercellular protein
transfer as recently described for latent cycle proteins [36] and the
lytic cycle protein BHRF1 [37], autologous mini-LCL were co-
cultured with MHC-mismatched LCL for 24 hours. T cell
recognition of the cell mixture, but neither component alone,
indicated that antigen released from cells undergoing lysis is
transferred to neighboring cells (Fig. 5B). Since BMRF1 and
BALF2 are highly abundant infected cell proteins, such a scenario
may also explain why LCL-stimulated T cell lines frequently
targeted these antigens.
Acyclovir treatment of LCL severely impairs late lytic
cycle antigen presentation on MHC II
To preclude transfer of infectious virus into patients, T cell lines
for clinical use are usually prepared by stimulation with acyclovir-
treated LCL [38,39]. Because acyclovir limits virus production by
interfering with late lytic cycle protein expression, we compared T
cell recognition of LCL cultured in the presence or absence of
acyclovir for two weeks. While acyclovir treatment did not affect
recognition of LCL by autoantigen and BMRF1-specific T cells,
recognition by BNRF1-specific T cells was severely impaired
(Fig. 6A). Similar results were obtained in co-culture experiments
of acyclovir-treated allogeneic LCL and autologous mini-LCL
(data not shown) demonstrating that treatment of LCL with this
drug selectively diminishes the presentation of late lytic cycle
antigens. To assess whether acyclovir-treated LCL still released
enough virus to reactivate late lytic cycle antigen-specific T cell
memory, CD4+ cells from peripheral blood were stimulated with
acyclovir-treated LCL as for clinical applications [38,39].
Recognition of LCL and virus-pulsed mini-LCL, but not untreated
mini-LCL, by these T cells indicated that acyclovir-treated LCL
are still able to expand virion antigen-specific T cells, albeit to
a much lesser extent than untreated LCL (Fig. 6B, and data not
shown).
DISCUSSION
The reconstitution of EBV-specific immunity in HSCT recipients
by the adoptive transfer of polyclonal virus-specific T cell lines has
provided an important proof of principle for immunotherapy of
EBV-associated tumors, and for cancer immunotherapy in general
[40–43]. Given the significant burden of EBV-associated tumors
worldwide, important future goals of this adoptive T cell therapy
are the introduction into mainstream clinical practice and the
extension to EBV-associated tumor entities other than PTLD
[21,40]. In a prelude to facilitate and expedite the preparation of
T cell lines enriched in disease-relevant T cell effectors, the
specificity of LCL-stimulated CD4+ TH cell preparations was
analyzed and followed over time. Early passage T cell lines from
all EBV-positive, but not virus-naı¨ve donors, responded against
lytic cycle and autoantigens. With further rounds of stimulation, all
T cell lines from healthy virus carriers responded predominantly
against lytic cycle antigens, while late passage T cell lines from IM
patients were often dominated by autoreactive rather than virus-
specific T cells. Surprisingly, latent cycle antigens of EBV were
barely targeted by LCL-stimulated and even mini-LCL-stimulated
T cell lines. This was unexpected because all latent cycle proteins
are expressed in LCL, and CD4+ T cells specific for latent
antigens have been detected in the peripheral blood of EBV-
seropositive donors, including three of the healthy virus carriers
analyzed in this study. These results indicate that latent cycle
antigen-specific TH cells are either a minor component of the
CD4+ T Cell Response to EBV
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LCL-reactive TH cell memory compartment, or peptides derived
from latent proteins are inefficiently presented on MHC II.
The second unexpected finding of this study was that LCL-
stimulated TH cell lines contained a high proportion of
autoreactive T cells, which either displayed a typical Th1, or
a novel ‘‘non-responder’’ phenotype. The latter T cells were
detected among T cell clones established from most of the lines
and dominated the late passage T cell line from IM7, which makes
them a relevant component of the LCL-stimulated TH cell
population. The definition of T cell effector functions is essential
for a more detailed characterization of this unusual T cell subset.
Autoreactive T cells of Th1 type were detected in EBV-infected
individuals only, and these specificities dominated the LCL-
stimulated T cell cultures from several IM patients, suggesting
a link between acute EBV infection and the induction of
autoreactive TH cell responses. Of note, autoreactive T cells have
recently been described as component of the CD4+ T cell response
that suppresses the outgrowth of LCL from newly EBV-infected B
cells in regression assays [44]. Thus, autoreactive T cells could play
a protective role against EBV infection, albeit at the expense of
damaging normal tissues. Autoimmunity, however, has not been
observed in HSCT recipients treated with LCL-stimulated T cell
lines, implying that these T cells are suppressed in vivo.
Nevertheless, several autoimmune diseases including multiple
sclerosis [45], systemic lupus erythematosus [46], and rheumatoid
arthritis [47] have been linked to EBV infection. For elucidating
whether these TH cells contribute to the pathogenesis of
autoimmune diseases, it will be important to identify the antigens
recognized by these T cells.
The most important finding of this study was the unexpected
immunodominance of lytic cycle antigens. Most of these antigens
were derived from late lytic gene products that belong to the group
of structural proteins of EBV. This immunodominance may be
a reflection of the efficient presentation of virion antigens on MHC
II following receptor-mediated uptake and processing in the lytic
compartment [22,48], and may explain why LCL-stimulated TH
cell lines target such a broad set of virion antigens. Besides
structural proteins, the lytic cycle antigens BCRF1, BMRF1, and
BALF2 also elicited TH cell responses, and responses to BALF2
prevailed over structural antigens in one of the donors. The
presentation of BMRF1 involved intercellular antigen transfer,
probably by release of protein from lytically infected cells and
uptake as exogenous protein by neighboring cells as described
previously [36,37]. Why these but not other lytic cycle proteins like
BZLF1 [22] are efficiently transferred between cells is not known,
but might reflect quantitative differences in protein expression
levels. By which pathways BALF2 and BCRF1 are presented is
currently not known.
The identification of the immunodominant and subdominant
antigens of LCL-stimulated TH cell preparations has several
clinical implications. First, in order to minimize residual infectious
viral particles within adoptively transferred T cells, most currently
applied clinical protocols use acyclovir to suppress virus pro-
duction in stimulator LCL [38,39]. Inhibition of late lytic cycle
protein expression by this drug, however, diminishes virion
antigen presentation and may lead to a preponderance of
autoantigen-specific TH cell responses. Thus, generating TH cell
lines enriched in late lytic cycle antigen-specific effectors may
necessitate the modification of current stimulation protocols.
Table 1. Summary of the antigens recognized by EBV-reactive
TH cell lines
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Donor dominant antigens subdominant antigens
IM1 BcLF1 BFRF3, BXLF2
IM2 BXLF2 BDLF1, BNRF1
IM5 BNRF1 BALF2
GB BNRF1 BXRF1, BORF1, BDLF1, BBRF3
JM BALF2 BDLF1, BXRF1, BALF4
DA BVRF2 BNRF1, BCRF1, BORF1, EBNA3C
MS BALF4 EBNA3C
SM BALF2, BNRF1 BMRF1
MA BMRF1, BNRF1 Nd
TK BORF1 Nd
The antigens recognized by the EBV-reactive TH cell lines were identified by
using PBMC or mini-LCL pulsed with single latent or lytic cycle proteins of EBV
as targets. Responses against dominant antigens were maintained up to fifty
restimulations, while responses against subdominant antigens were detected at
early passages of the TH cell lines only. Nd, not determined.
doi:10.1371/journal.pone.0000583.t001..
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Second, the failure of most of the autoreactive T cells to recognize
PBMC and DC suggests that using these cells as stimulators may
reduce the autoreactive component in TH cell preparations.
Evidence in support of this proposition has been obtained in recent
experiments showing that significantly fewer rounds of stimulation
are required to generate virion-specific TH cell lines when using
virus-pulsed PBMC rather than LCL as APC (data not shown).
Such modified stimulation protocols would further expedite the
preparation of EBV-specific TH cell lines by obviating the lengthy
procedure of establishing LCL. Third, the inefficient expansion of
latent cycle antigen-specific TH cells by LCL stimulation, most
importantly CD4+ T cells specific for EBNA1 which is expressed
in all EBV-associated malignancies, implies that incorporating
these effectors into the T cell preparations may further improve
their clinical efficacy. Finally, the identification of the immuno-
dominant targets of the EBV-specific TH cell response provides
insight into the role of this T cell subset in the control of EBV
infection. By recognizing and eliminating newly infected cells,
virion-specific TH cells limit the spreading of infection and keep
the pool of latently infected B cells small [22,49]. Interestingly,
LCL-stimulated CD8+ T cells are predominantly directed against
latent cycle as well as immediate early and early lytic cycle
antigens [14–17,50]. Targeting mostly non-overlapping sets of
viral proteins and different phases of the virus’ life cycle implies
that CD4+ and CD8+ T cells complement each other in
establishing protective immunity against EBV.
Although most EBV-associated tumors express MHC II, the low
number of tumor cells undergoing lytic replication in vivo
challenges the concept of an analogous role of virion-specific
CD4+ T cells in tumor control. However, the efficient transfer of
virion antigens to bystander cells by receptor-mediated uptake of
released viral particles, which results in TH cell recognition of
target cells incubated with less than one viral particle per cell,
suggests that only few tumor cells undergoing lysis may sensitize
a large proportion of tumor cells for TH cell recognition.
Moreover, radio/chemotherapy of EBV-positive tumors in vivo
is associated with the induction of lytic replication in a significant
portion of tumor cells, and more selective compounds for
reactivating EBV from latency are currently evaluated [51,52].
The combination of lytic cycle induction strategies with T cell
therapy may even be more effective than either approach alone
and may further improve the clinical effectiveness of this form of
immunotherapy and the long term survival of patients.
SUPPORTING INFORMATION
Figure S1 Latent cycle proteins of EBV are not the dominant
targets of mini-LCL stimulated TH cell lines. Mini-LCL-stimulated
CD4+ T cell lines from donor DA and JM were tested for
recognition of latent cycle proteins of EBV by using PBMC or DC
preincubated for 24 hours with recombinant latent cycle proteins
as targets in T cell cytokine secretion assays. The T cells from
donor JM failed to show above-background response against any
of the latent cycle proteins whereas the T cells from donor DA
showed only minimal response against EBNA3C.
Found at: doi:10.1371/journal.pone.0000583.s001 (0.91 MB EPS)
Figure S2 Late passage LCL-stimulated CD4+ T cell lines are
oligoclonal. Single cell clones of the LCL-stimulated T cell line
from donor MA at passage 17 were tested for recognition of LCL,
mini-LCL, and mini-LCL pulsed with BNRF1 or BMRF1, the
antigens recognized by the parental T cell line. Of 16 clones
analyzed, 5 were BMRF1-specific, 1 was BNRF1-specific, 4
recognized LCL but not mini-LCL, 2 showed significant responses
against LCL and mini-LCL, and 4 failed to secrete IFN-c in
response to any of the target cells.
Found at: doi:10.1371/journal.pone.0000583.s002 (0.76 MB EPS)
Figure S3 T cell receptor Vb chain analysis of late passage T
cell lines. T cell receptor Vb chain expression of TH cell lines, that
had shown lytic cycle antigen specificity, was analyzed by RT-
PCR using Vb chain specific primers and subsequent Southern
blot hybridization of the PCR products. Even late passage T cell
lines still expressed more than one Vb chain, demonstrating that
the T cell lines were still oligoclonal. The TH cell line from donor
SM, that had already lost mini-LCL reactivity after four
stimulations, still expressed multiple Vb chains, indicating that
many different lytic cycle antigen-specific TH cells may exist in
healthy virus carriers.
Found at: doi:10.1371/journal.pone.0000583.s003 (5.54 MB EPS)
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CD4+ T Cell Response to EBV
PLoS ONE | www.plosone.org 9 July 2007 | Issue 7 | e583
ACKNOWLEDGMENTS
We thank Brigitte Lechner and Heike Christoph for providing outstanding
technical assistance.
Author Contributions
Conceived and designed the experiments: GB JM UB. Performed the
experiments: DA. Analyzed the data: JM DA UB. Contributed reagents/
materials/analysis tools: GB HB AP SB AM KW. Wrote the paper: JM DA
UB.
REFERENCES
1. Kuppers R (2003) B cells under influence: transformation of B cells by Epstein-
Barr virus. Nat Rev Immunol 3: 801–812.
2. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev
Cancer 4: 757–768.
3. Rickinson AB, Kieff E (2006) Epstein-Barr virus. In: Knipe DM, Howley PM,
eds. Field’s Virology. 5th ed. Philadelphia: Lippincott-Raven. pp 2655–2700.
4. Papesch M, Watkins R (2001) Epstein-Barr virus infectious mononucleosis. Clin
Otolaryngol Allied Sci 26: 3–8.
5. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and
the origins of associated lymphomas. N Engl J Med 350: 1328–1337.
6. Kieff E, Rickinson AB (2006) Epstein-Barr virus and its replication. In:
Knipe DM, Howley PM, eds. Field’s Virology. 5th ed. Philadelphia: Lippincott-
Raven. pp 2603–2654.
7. Dolcetti R, Masucci MG (2003) Epstein-Barr virus: induction and control of cell
transformation. J Cell Physiol 196: 207–218.
8. Gottschalk S, Rooney CM, Heslop HE (2005) Post-transplant lymphoprolifera-
tive disorders. Annu Rev Med 56: 29–44.
9. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, et al. (1995) Use of gene-
modified virus-specific T lymphocytes to control Epstein-Barr-virus-related
lymphoproliferation. Lancet 345: 9–13.
10. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, et al. (1998) Infusion of
cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced
lymphoma in allogeneic transplant recipients. Blood 92: 1549–1555.
11. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, et al. (2002) Treatment of
Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with
partly HLA-matched allogeneic cytotoxic T cells. Lancet 360: 436–442.
12. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, et al. (1992)
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant
vaccinia: implications for vaccine development. J Exp Med 176: 169–176.
13. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, et al. (1992)
Identification of target antigens for the human cytotoxic T cell response to
Epstein-Barr virus (EBV): implications for the immune control of EBV-positive
malignancies. J Exp Med 176: 157–168.
14. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, et al. (1997)
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-
Barr virus-induced cytotoxic T cell response. J Exp Med 185: 1605–1617.
15. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O’Callaghan CA, et al. (1999) A
re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus
carriers. J Immunol 162: 1827–1835.
16. Khanna R, Burrows SR (2000) Role of cytotoxic T lymphocytes in Epstein-Barr
virus-associated diseases. Annu Rev Microbiol 54: 19–48.
17. Landais E, Saulquin X, Houssaint E (2005) The human T cell immune response
to Epstein-Barr virus. Int J Dev Biol 49: 285–292.
18. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, et al. (2007)
Allogeneic cytotoxic T cell therapy for EBV-positive post transplant lympho-
proliferative disease: results of a phase II multicentre clinical trial. Blood In press.
19. Moss P, Rickinson A (2005) Cellular immunotherapy for viral infection after
HSC transplantation. Nat Rev Immunol 5: 9–20.
20. Davis JE, Moss DJ (2004) Treatment options for post-transplant lymphoproli-
ferative disorder and other Epstein-Barr virus-associated malignancies. Tissue
Antigens 63: 285–292.
21. Gottschalk S, Heslop HE, Rooney CM (2005) Adoptive immunotherapy for
EBV-associated malignancies. Leuk Lymphoma 46: 1–10.
22. Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, et al. (2006)
Control of Epstein-Barr virus infection in vitro by T helper cells specific for
virion glycoproteins. J Exp Med 203: 995–1006.
23. Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, et al. (2004)
Establishment and characterization of a bank of cytotoxic T lymphocytes for
immunotherapy of epstein-barr virus-associated diseases. J Immunother 27:
309–316.
24. Nimmerjahn F, Kobelt D, Steinkasserer A, Menke A, Hobom G, et al. (2003)
Efficient generation and expansion of antigen-specific CD4+ T cells by
recombinant influenza viruses. Eur J Immunol 33: 3331–3341.
25. Gussoni E, Panzara MA, Steinman L (1997) Evaluating Human T Cell Receptor
Gene Expression by PCR. Current protocols in Immunology: John Wiley &
Sons. pp 10.26.11–10.26.14.
26. Mautner J, Pich D, Nimmerjahn F, Milosevic S, Adhikary D, et al. (2004)
Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+
T helper cells. Eur J Immunol 34: 2500–2509.
27. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, et al. (1999)
Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.
J Clin Microbiol 37: 132–136.
28. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, et al. (2003)
Major histocompatibility complex class II-restricted presentation of a cytosolic
antigen by autophagy. Eur J Immunol 33: 1250–1259.
29. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, et al. (2006) Treatment
of solid organ transplant recipients with autologous Epstein Barr virus-specific
cytotoxic T lymphocytes (CTLs). Blood 108: 2942–2949.
30. Khanna R, Burrows SR, Steigerwald-Mullen PM, Thomson SA, Kurilla MG, et
al. (1995) Isolation of cytotoxic T lymphocytes from healthy seropositive
individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen
1: implications for viral persistence and tumor surveillance. Virology 214:
633–637.
31. Khanna R, Burrows SR, Thomson SA, Moss DJ, Cresswell P, et al. (1997) Class
I processing-defective Burkitt’s lymphoma cells are recognized efficiently by
CD4+ EBV-specific CTLs. J Immunol 158: 3619–3625.
32. Munz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, et al. (2000)
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr
virus nuclear antigen EBNA1. J Exp Med 191: 1649–1660.
33. Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, et al. (2001)
Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for
human CD4(+) T-helper 1 responses. J Virol 75: 8649–8659.
34. Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, et al. (2002) B cells
immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently
reactivate specific cytotoxic T cells. Blood 100: 1755–1764.
35. Johannsen E, Luftig M, Chase MR, Weicksel S, Cahir-McFarland E, et al.
(2004) Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A 101:
16286–16291.
36. Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, et al. (2006) A role for
intercellular antigen transfer in the recognition of EBV-transformed B cell lines
by EBV nuclear antigen-specific CD4+ T cells. J Immunol 177: 3746–3756.
37. Landais E, Saulquin X, Bonneville M, Houssaint E (2005) Long-term MHC
class II presentation of the EBV lytic protein BHRF1 by EBV latently infected
b cells following capture of BHRF1 antigen. J Immunol 175: 7939–7946.
38. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, et al. (2004)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease.
J Exp Med 200: 1623–1633.
39. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE (1998)
Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst
Monogr. pp 89–93.
40. Tey SK, Bollard CM, Heslop HE (2006) Adoptive T-cell transfer in cancer
immunotherapy. Immunol Cell Biol 84: 281–289.
41. Foster AE, Rooney CM (2006) Improving T cell therapy for cancer. Expert
Opin Biol Ther 6: 215–229.
42. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD (2003) Adoptive
immunotherapy: engineering T cell responses as biologic weapons for tumor
mass destruction. Cancer Cell 3: 431–437.
43. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP (2006) Adoptive
immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383–393.
44. Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB (2005)
Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves
virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell
reactivity. J Virol 79: 5477–5488.
45. Haahr S, Hollsberg P (2006) Multiple sclerosis is linked to Epstein-Barr virus
infection. Rev Med Virol 16: 297–310.
46. Poole BD, Scofield RH, Harley JB, James JA (2006) Epstein-Barr virus and
molecular mimicry in systemic lupus erythematosus. Autoimmunity 39: 63–70.
47. Sawada S, Takei M (2005) Epstein-Barr virus etiology in rheumatoid synovitis.
Autoimmun Rev 4: 106–110.
48. Feederle R, Neuhierl B, Baldwin G, Bannert H, Hub B, et al. (2006) Epstein-
Barr virus BNRF1 protein allows efficient transfer from the endosomal
compartment to the nucleus of primary B lymphocytes. J Virol 80: 9435–9443.
49. Heller KN, Gurer C, Munz C (2006) Virus-specific CD4+ T cells: ready for
direct attack. J Exp Med 203: 805–808.
50. Pudney VA, Leese AM, Rickinson AB, Hislop AD (2005) CD8+ immunodo-
minance among Epstein-Barr virus lytic cycle antigens directly reflects the
efficiency of antigen presentation in lytically infected cells. J Exp Med 201:
349–360.
51. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC (2002)
Chemotherapy induces lytic EBV replication and confers ganciclovir suscepti-
bility to EBV-positive epithelial cell tumors. Cancer Res 62: 1920–1926.
52. Israel BF, Kenney SC (2003) Virally targeted therapies for EBV-associated
malignancies. Oncogene 22: 5122–5130.
CD4+ T Cell Response to EBV
PLoS ONE | www.plosone.org 10 July 2007 | Issue 7 | e583
